Daraxonrasib delivered a 58% confirmed objective response rate in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (n=40; 95% CI: 41–73), with 6‑month progression-free and overall survival estimates of 84% (95% CI: 68–93) and 90% (95% CI: 76–96), respectively. As monotherapy in a separate first-line cohort (approximately n=40), the agent posted a 47% ORR (95% CI: 31–64), a 92% disease control rate (95% CI: 79–98), and 6‑month PFS and OS estimates of 71% (95% CI: 53–83) and 83% (95% CI: 67–92). Safety was manageable across cohorts, with no Grade 5 events in combination and no Grade 4/5 in monotherapy.
The core update centers on two Phase 1/2 datasets presented at AACR from Revolution Medicines’ RAS(ON) multi-selective inhibitor daraxonrasib in previously untreated RAS‑mutant metastatic PDAC. In RMC‑GI‑102, daraxonrasib 200 mg QD plus gemcitabine/nab‑paclitaxel administered on Days 1 and 15 of 28‑day cycles showed Grade ≥3 treatment-related anemia (33%), decreased neutrophils (20%), and fatigue (18%); discontinuations were 5% for daraxonrasib and 15% for chemotherapy, with mean dose intensities of 82% and 80%. In RMC‑6236‑001, daraxonrasib 300 mg QD (21‑day cycles) yielded Grade ≥3 rash, diarrhea, and stomatitis among the most frequent events; overall Grade ≥3 TRAEs occurred in 38%, with mean dose intensity of 84%. The readout follows the company’s announcement that the pivotal Phase 3 RASolute 302 trial in previously treated metastatic PDAC met PFS and OS endpoints.
Strategically, the company is prosecuting a dual path in first line: pairing daraxonrasib with a widely adopted chemotherapy backbone while advancing a chemo‑sparing monotherapy that, if sustained, could reset expectations for an oral RAS‑targeted approach in PDAC. The choice of a Day 1/15 gemcitabine/nab‑paclitaxel schedule prioritizes tolerability and dose intensity, aligning with contemporary practice patterns that mitigate myelosuppression. Against historical controls, the combination ORR appears elevated for GnP-based regimens, though the small sample and immature survival demand caution. Running monotherapy in parallel gives the program optionality for patients unfit for intensive chemotherapy and creates a potential operational and commercial differentiator if randomized data hold.
A notable tension is biomarker strategy. Daraxonrasib targets RAS(ON) across mutant and wild-type, and the company reports an OS benefit in the second‑line pivotal study across the intent‑to‑treat population, including tumors without identified RAS mutations. If borne out in filings, that could reduce dependence on upfront molecular testing in PDAC, expand eligibility, and accelerate accrual—while raising regulatory and payer questions on mechanism and labeling. It also distinguishes daraxonrasib from allele‑selective competitors vying for G12D and other subsets, potentially positioning it as a backbone therapy rather than a niche agent.
For sites and CROs, the program is enrollment-friendly in PDAC where RAS mutations are prevalent, with dosing and visit schedules that fit standard workflows. The combination regimen will require routine hematologic monitoring, but early neutropenia rates on the biweekly schedule may be more manageable than traditional weekly GnP. Monotherapy shifts operational burden toward managing dermatologic and GI toxicities and adherence for an oral agent, potentially easing infusion chair constraints and pharmacy logistics. Regulators will focus on durability, survival separation in randomized settings, and the necessity—or not—of a companion diagnostic. Vendors supporting safety signal detection, rash management algorithms, and adherence monitoring will be particularly relevant.
Next, attention turns to maturation of PFS and OS from these Phase 1/2 cohorts, the design details and timelines of the ongoing first-line Phase 3 RASolute 303, and whether biomarker requirements evolve in light of the 302 result. Key risks include regression of early response and survival estimates with longer follow-up, competitive readouts from G12D‑selective regimens that could redefine standard backbones, and the strategic fork between monotherapy and combination paths if safety or efficacy diverge at scale. Watch for subgroup analyses by RAS variant, dose modification patterns under real‑world intensity, and any regulatory signals on pathway-agnostic labeling in PDAC.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
